A monoclonal anti-idiotypic antibody against an anti-acetylcholine receptor antibody from a patient with myasthenia gravis was shown to bind the cholinergic ligand alpha-bungarotoxin. This binding could be inhibited by other cholinergic ligands, both antagonists and agonists. The anti-idiotype was also able to elicit the production of anti-receptor antibodies in mice. Thus, the anti-idiotype had functional properties similar to those of the original antigen, the acetylcholine receptor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-3083.1984.tb00958.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-Idiotypic Antibody as a Booster Vaccine Against Respiratory Syncytial Virus.
Vaccines (Basel)
January 2025
Infectious Diseases and Vaccine Research, Merck & Co., Inc., Rahway, NJ 07065, USA.
The respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in children and adults. With nearly everyone infected by the age of five, there is an opportunity to develop booster vaccines that enhance B-cell immunity, promoting potent and broadly neutralizing antibodies. One potential approach involves using anti-idiotypic antibodies (anti-IDs) to mimic specific antigenic sites and enhance preexisting immunity in an epitope-specific manner.
View Article and Find Full Text PDFChondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma.
Cancers (Basel)
September 2024
St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King's College London, London SE1 9RT, UK.
Immunotherapies, including checkpoint inhibitor antibodies, have precipitated significant improvements in clinical outcomes for melanoma. However, approximately half of patients do not benefit from approved treatments. Additionally, apart from Tebentafusp, which is approved for the treatment of uveal melanoma, there is a lack of immunotherapies directly focused on melanoma cells.
View Article and Find Full Text PDFTargeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies.
Cell Rep
October 2024
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA; Department of Global Health, University of Washington, Seattle, WA 98195, USA. Electronic address:
Article Synopsis
- Respiratory syncytial virus (RSV) poses serious health risks for young children and elderly individuals, with current vaccines mainly available for adults over 60 and temporary protection for infants through maternal antibodies.
- Researchers have developed a new type of vaccine that uses an anti-idiotypic monoclonal antibody (ai-mAb) specifically designed to target B cell receptors capable of producing RSV-neutralizing antibodies.
- This novel approach effectively engages the right B cells without triggering unwanted immune responses, showcasing potential for a more effective infant vaccine against RSV.
Basophil FceRI expression-A management tool in anti-IgE treatment of allergic asthma.
Pediatr Pulmonol
December 2024
Department of Clinical Medicine, Department of Clinical Immunology, Aarhus University Hospital, Aarhus University, Aarhus, Denmark.
Background: Immune-based therapy targeting immunoglobulin E (IgE), anti-IgE treatment, has emerged as an adjunct treatment for children with severe allergic asthma. After start of anti-IgE treatment, an effect of the treatment cannot be monitored by Total-IgE, because current methods measure both bound and free IgE molecules. Basophil activation test may be very useful for monitoring anti-IgE treatment efficacy.
View Article and Find Full Text PDFBelimumab concentration measurements using a homologous anti-idiotype immunoassay.
J Immunol Methods
September 2024
Biologics Laboratory, Sanquin Diagnostic Services, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands. Electronic address:
Monitoring belimumab concentrations in patients can be a valuable tool for assessing treatment response and for personalizing drug doses. Various assay formats may be used to measure concentrations of therapeutic monoclonal antibodies. A particularly useful format involves the use of anti-idiotype monoclonal antibodies, selected to be highly specific to the antibody of interest.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!